Community Stories & Education
Life Through a Different Lens: They Just Talked About Eyes!
Christine and Anthony Gonzales dreamed of having a large family and were thrilled when their first child, Iliana, was born in August 2018. However, within a few months, their excitement turned to concern. “About a week after Iliana received her…
Most Recent
Opus Genetics in Alignment with FDA for Phase 3 LCA5 Gene Therapy Clinical Trial
Opus Genetics has reached alignment with the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design…
Report from 2026 ARVO: Several Emerging LCA Gene Therapies are Restoring Vision
In reporting on emerging therapies for LCA and other retinal diseases, my mantra has always been “just the facts.” If…
LCA5 Gene Therapy Development Could be Accelerated Thanks to New FDA Rare Disease Review Process
Opus Genetics’ emerging LCA5 gene therapy, OPGx-LCA5, has been accepted into the US Food & Drug Administration’s (FDA) new Rare…
Light at the End of the Tunnel: LCA6 Gene Therapy Advances Toward Clinical Trial
I am excited to report on impressive progress in the development of Odylia Therapeutics’ emerging gene therapy for retinal degeneration…
A Vision-Restoring XLRP Gene Therapy Gets New Life: MeiraGTx to Seek FDA Approval
In May 2025, Johnson & Johnson (J&J) announced that though its emerging gene therapy bota-vec for X-linked retinitis pigmentosa (XLRP)…
LCA5 Gene Therapy Provides Vision Improvements in Clinical Trial
Nothing is more hopeful or gratifying for the retinal disease community than an emerging or FDA-approved therapy that provides vision…
Promising RNA Therapies for LCA10 and USH2A Move Back into Clinical Trials
Moving emerging therapies through clinical trials and across the finish line is often challenging—and in some cases, harrowing. Many treatments…
Reports on Gene Therapy Advances: A Highlight from the 2025 Hope in Focus Conference in Minneapolis
Gene therapy is unequivocally the most advanced approach for treating retinal diseases like Leber congenital amaurosis (LCA). Of course, there’s LUXTURNA® which is…
Diverse Emerging Therapies Featured at the 2025 Hope in Focus Conference in Minneapolis
The development of diverse treatment approaches for Leber congenital amaurosis (LCA) is necessary because no single modality will work for everyone affected….
LCA Research Updates from FFB
BlueRock Photoreceptor Replacement Therapy Moving into a Clinical Trial
The development of gene therapies for inherited retinal diseases (IRDs) took off when young adults and children showed significant vision improvements in an early clinical trial.
Foundation Fighting Blindness and CheckedUp® Partner to Educate Retinal-Disease Patients About Research, Resources, and Emerging Therapies During Doctor Visits
The Foundation Fighting Blindness (the Foundation) and CheckedUp have formed a collaborative partnership to deliver patient-friendly diagnostic and disease-management information to people with retinal diseases such as age-related macular degeneration, retinitis pigmentosa, and Stargardt disease during their visits to eye doctors.
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
AN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.